TY - JOUR
T1 - Clostridium difficile
T2 - new therapeutic options
AU - Balagopal, Ashwin
AU - Sears, Cynthia L.
PY - 2007/10/1
Y1 - 2007/10/1
N2 - Clostridium difficile disease is the major, known cause of nosocomial diarrhea and is an emerging cause of community-associated diarrhea. Recent outbreaks due to a strain of apparent increased virulence, BI/NAP1, and recognition of increasing metronidazole treatment failures as well as the morbidity associated with recurrent C. difficile disease have begun to spur studies to develop new therapies for C. difficile disease. Nitazoxanide, tolevamer, ramoplanin, and rifaximin are key agents being evaluated as new therapies for C. difficile disease. For now, vancomycin or metronidazole combined with discontinuation of antibiotics, when feasible, and expert infection control remain the mainstays of C. difficile disease management.
AB - Clostridium difficile disease is the major, known cause of nosocomial diarrhea and is an emerging cause of community-associated diarrhea. Recent outbreaks due to a strain of apparent increased virulence, BI/NAP1, and recognition of increasing metronidazole treatment failures as well as the morbidity associated with recurrent C. difficile disease have begun to spur studies to develop new therapies for C. difficile disease. Nitazoxanide, tolevamer, ramoplanin, and rifaximin are key agents being evaluated as new therapies for C. difficile disease. For now, vancomycin or metronidazole combined with discontinuation of antibiotics, when feasible, and expert infection control remain the mainstays of C. difficile disease management.
UR - http://www.scopus.com/inward/record.url?scp=35248851268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35248851268&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2007.05.007
DO - 10.1016/j.coph.2007.05.007
M3 - Review article
C2 - 17644040
AN - SCOPUS:35248851268
SN - 1471-4892
VL - 7
SP - 455
EP - 458
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
IS - 5
ER -